Obermatt
See Similar Stocks →

Castle Biosciences

NMQ:CSTL · US14843C1053
Health Care Providers & ServicesMedium

360

10
Profit price81
Owner Earnings Yield1
Dividend Yield1
Price/Sales56
EV / Gross Profit83
Price/Book66
Return on Capital16
Cash Return on Capital22
Return on Equity40
EBIT Margin12
Gross Profitability71
Accruals26
Owner Earnings Margin18
Sales growth25
Profit growth43
Reinvestment19
Price momentum63
Debt load74
Refinancing74
Debt Payback1
Liquidity7
Analyst ratings100
Opinion Changes50
Price Target Upside96
Market mood62
Value Creation2/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Castle Biosciences doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryUSA
IndustryHealth Care Providers & Services
SizeMedium
TypePublic Company
ExchangeNASDAQGM
Founded2007
Employees643
Websitecastlebiosciences.com
ISINUS14843C1053
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
Health DiagnosticsDermatologyGeneticsGastroenterologyPsychiatryOncologyBiotechnologyHealth Care

Description

Castle Biosciences, Inc. (Castle Biosciences) operates as a molecular diagnostics company which offers innovative test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus (BE), atopic dermatitis (AD…

Analysis

Weak and unloved

Castle Biosciences, Inc. scores below average on quality and is priced accordingly, a low-conviction position in either direction.

Valuation data is not available for this company.

Growth is tepid; the safety picture is stretched. The company scores 2/20 on our value-creation score: not creating value.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
74
2023202420252026

All-time high

74

Jun 2026

All-time low

25

Jan 2025

Average rank

47

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
56
7
12
3
Price/Earnings
97
4
78
24
Price/Book
66
59
80
59
Dividend Yield
1
1
1
1
Value (overall)
78
7
35
26

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Castle Biosciences with its peers
Bicara Therapeutics
NMQ:BCAX
43
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Janux Therapeutics
NMQ:JANX
41
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Annexon
NSQ:ANNX
44
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
BillionToOne
NSQ:BLLN
55
CountryUSA
IndustryHealth Care Providers & Services
SizeSmall
Full Stock Analysis →
Fulgent Genetics
NMQ:FLGT
4
CountryUSA
IndustryHealth Care Providers & Services
SizeMedium
Full Stock Analysis →
Talkspace
NAQ:TALK
56
CountryUSA
IndustryHealth Care Providers & Services
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →